Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 22Terminated 7Active not recruiting 5Recruiting 4Unknown 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Lung Neoplasms 1Esophageal Neoplasms 1

Interventions

pembrolizumab 2Propranolol 2talimogene laherparepvec 1sargramostim 1romiplostim 1propranolol CR 1imisopasem manganese 1dabrafenib 1cobimetinib 1aldesleukin 1Vemurafenib 1Vaccines 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Paclitaxel 1Nivolumab 1Nanoparticles 1Ketones 1Interleukin-2 1Glucose 1Diet Therapy 1CA-4948 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Melanoma × Paclitaxel × Clear all
NCT00278122 2013-12-10

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

University of Virginia

Phase 2 Suspended
42 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡